Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Palliative Epirubicin, Oxaliplatin & Capecitabine (EOX) Chemotherapy Combined With Omega-3 Fish Oil Infusion (Omegaven) in Patients With Oesophagogastric Carcinoma

NCT01870791 is registered in ClinicalTrials.gov with University Hospitals, Leicester as lead sponsor.

NCT NCT01870791
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01870791 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Palliative Epirubicin, Oxaliplatin & Capecitabine (EOX) Chemotherapy Combined With Omega-3 Fish Oil Infusion (Omegaven) in Patients With Oesophagogastric Carcinoma
Lead sponsor
University Hospitals, Leicester
Phase
Phase 2
Overall status
Terminated
Start date
May 31, 2012
Completion date
December 31, 2015
Enrollment
21 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal neoplasm, gastric neoplasm